Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130315211434im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
This study tests the effectiveness of a behavioral intervention to reduce sexual risk behavior in HIV-positive, methamphetamine-using men who have sex with men (MSM). It builds on the findings of a previous study (R01 DA012116, "Promoting safer sex in HIV+ homosexual and bisexual men who use methamphetamine"). That study achieved significant short-term results that eroded over time. Accordingly, this study hypothesizes that the addition of a maintenance component to the already proven counseling and educational components of the treatment model will result in longer-lasting positive effects.
Condition | Intervention | Phase |
---|---|---|
HIV Infections Substance Abuse Sexually Transmitted Diseases |
Behavioral: EDGE counseling, no maintenance Behavioral: EDGE counseling, plus maintenance Behavioral: Attention control |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
Official Title: | Behavior Change and Maintenance Intervention for HIV+ MSM Methamphetamine Users |
- Reduction of defined sexual risk behaviors [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
Enrollment: | 429 |
Study Start Date: | February 2007 |
Study Completion Date: | April 2012 |
Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
|
Behavioral: EDGE counseling, no maintenance
Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
|
Experimental: 2
Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
|
Behavioral: EDGE counseling, plus maintenance
Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
|
Active Comparator: 3
An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
|
Behavioral: Attention control
An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
|
Detailed Description:
Methamphetamine use by MSM has been consistently associated with increased HIV transmission. In the previous funding period we demonstrated reductions in transmission risk behavior associated with participation in our behavioral intervention; however, these improvements eroded over time, underscoring the need to develop and test interventions designed to enhance longer-term behavior change. The objective of this study is to evaluate the efficacy of an intervention designed to maintain reductions in high-risk sexual practices achieved by methamphetamine-using HIV+ MSM. Three major questions addressed are: 1) Can methamphetamine-using HIV+ MSM modify their high-risk sexual practices over an extended (16-month) period? 2) Do "group maintenance sessions" result in less erosion of behavioral improvements? 3) Are the underlying mechanisms the same for acquisition and maintenance of behavior change? We will assign 450 sexually active HIV+ MSM who regularly use methamphetamine and who have had unprotected sex with an HIV-negative or unknown-status partner to one of three conditions: 1) an eight-session intervention, combining client-centered motivational interviewing and structured behavioral counseling to address five intervention domains (context of unsafe sex/drug use; condom use; safer sex negotiation; disclosure; and enhancement of social supports); 2) the same eight counseling sessions (i.e., identical to condition 1 above), plus eight group-format safer sex maintenance sessions, which utilize clinical strategies from relapse prevention to identify high-risk situations and develop effective coping strategies; or 3) an attention-control condition that is time-equivalent to condition 2 above, and addresses diet, exercise, and HIV. Thus we will determine whether longer-term maintenance of safer sex behaviors is possible among HIV+ methamphetamine-using MSM, a population that remains at very high risk of HIV transmission, and for which substitution therapies to promote cessation and risk reduction are not yet available.
![](https://webarchive.library.unt.edu/web/20130315211434im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV+
- Used methamphetamine at least twice in last two months
- At least some recent sexual partners were male
- At least some recent sexual activity has been high-risk for transmission of HIV
Exclusion Criteria:
- Current major psychiatric diagnosis
- Only HIV+ sex partners in past two months
- Consistently protected sex with HIV- or serostatus-unknown partners in last two months
- Sexually inactive in last two months
- Found out about HIV+ status less than two months ago
![](https://webarchive.library.unt.edu/web/20130315211434im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, California | |
Webster Building, 3500 Fifth Ave., Suite 102 | |
San Diego, California, United States, 92103 |
Principal Investigator: | Thomas L. Patterson, Ph.D. | University of California, San Diego |
![](https://webarchive.library.unt.edu/web/20130315211434im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided by University of California, San Diego
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Thomas L. Patterson, Principal Investigator, University of California, San Diego |
ClinicalTrials.gov Identifier: | NCT00432926 History of Changes |
Other Study ID Numbers: | R01 DA021115, R01DA021115 |
Study First Received: | February 6, 2007 |
Last Updated: | September 27, 2012 |
Health Authority: | United States: Federal Government |
Keywords provided by University of California, San Diego:
HIV STDs Methamphetamine abuse MSM HIV Seronegativity |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Sexually Transmitted Diseases Substance-Related Disorders Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Infection Genital Diseases, Male Genital Diseases, Female |
Mental Disorders Methamphetamine Amphetamine Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Central Nervous System Agents Therapeutic Uses Adrenergic Agents |
ClinicalTrials.gov processed this record on March 14, 2013